The Cross-Border Biotech Blog

MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for May 25th, 2015! The past week saw Endo International announce the acquisition of Par Pharmaceutical holdings in a $8 billion deal, creating a speciality pharmaceutical company with a generics business. For details this story, as well as for the rest of the week’s news, continue reading the […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for May 22nd, 2015! Cell Rep. 2015 May 21. doi: 10.1016/j.celrep.2015.04.056 Single Transcription Factor Conversion of Human Blood Fate to NPCs with CNS and PNS Developmental Capacity   BMC Biotechnol. 2015 May 16;15(1):31. Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.   Dev Cell. 2015 May 13. […]

read more


Test_HighRes_Part_9

Cost-Effectiveness and Affordability of New Medicines (2) “Is the new drug cost-effective versus the standard of care?” will be addressed in this and the following blog. The following two definitions are from the glossary on the NICE website (http://www.nice.org.uk/glossary).  Cost-effectiveness analysis: Cost-effectiveness analysis assesses the cost of achieving a benefit by different means. The benefits […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for May 11th, 2015! Endo International has announced the acquisition of a portfolio of pain, anti-infective and cardiovascular products from a subsidiary of Aspen Holdings, and M Pharmaceutical Inc. indicated it will be acquiring intellectual property rights associated with neural gastrointestinal stimulators from Trimtec Biomedical. The past week […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for May 8th, 2015! Proc Natl Acad Sci U S A. 2015 May 4. pii: 201419895. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.   Proc Natl Acad Sci U S A. 2015 May 4. pii: 201506755. CD4 mimetics sensitize HIV-1-infected cells to ADCC.   Nat […]

read more


BBB_Part8_logo

Cost-Effectiveness and Affordability of New Medicines (1) There were 5,408 medicines in clinical development globally in December 2011, many of which were being developed for multiple indications (PhRMA, the Pharmaceutical Research and Manufacturers of America; http://www.phrma.org/pipeline). It is possible that up to 1,000 of these medicines will eventually be approved – based on approval rates […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for May 4th, 2015! The past week saw significant activity in the financing space, with Merus Labs, Resverlogix and Helix BioPharma announcing successful financings, among others. For details the major stories, as well as for the rest of the week’s news, continue reading this week’s Monday Deal Review! […]

read more


The fourth annual Bloom Burton & Co. Healthcare Investor Conference

An exciting morning for Bloom Burton, as we opened the TSX in anticipation of our fourth annual Healthcare Investor Conference. While it may be named the Bloom Burton & Co. Healthcare Investor Conference, our aim each year is to place the great Canadian healthcare and biotechnology companies in the spotlight and give them the chance […]

read more


Apollo_Part1

Email: snicolle@capebearadvisors.com   The Internet of Healthcare Things All of a sudden, the Internet of Things is starting to connect my house and my car to the Internet. For example, I can monitor and control my thermostat remotely from my iPhone so my house warms up before I get home from a long trip. I […]

read more